Onkure Therapeutics Inc
OKUR2.570USD
+0.090+3.63%
收盘 09/19, 16:00（美东）报价延迟15分钟
34.77M总市值
亏损市盈率 TTM
关于 Onkure Therapeutics Inc 公司
OnKure Therapeutics, Inc.（前身为 Reneo Pharmaceuticals, Inc.）是一家临床阶段的生物制药公司，专注于发现和开发精准药物，这些药物针对的是现有疗法无法满足的、经过生物学验证的癌症驱动因素。该公司正在利用基于结构的药物设计平台，建立一个强大的肿瘤无关候选药物产品线。该公司正在开发选择性 PI3KαH1047R 抑制剂 OKI-219 作为其主要项目。OKI-219 正在针对 PI3KαH1047R 突变的实体瘤患者（包括乳腺癌）进行 I 期临床试验评估。该公司还专注于靶向致癌 PI3Kα，并有多个旨在靶向这一关键致癌基因的项目。
公司简介
公司代码OKUR
公司名称Onkure Therapeutics Inc
上市日期Apr 09, 2021
CEODr. Nicholas A. Saccomano, Ph.D.
员工数量46
证券类型Ordinary Share
年结日Apr 09
公司地址6707 Winchester Circle, Suite 400
城市BOULDER
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编80301
电话17203072892
网址https://onkuretherapeutics.com/
公司代码OKUR
上市日期Apr 09, 2021
CEODr. Nicholas A. Saccomano, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Isaac Manke, Ph.D.
Dr. Isaac Manke, Ph.D.
Independent Director
Independent Director
9.78K
+181.93%
Mr. Michael (Mike) Grey
Mr. Michael (Mike) Grey
Executive Director
Executive Director
--
--
Mr. Jason A. Leverone, CPA
Mr. Jason A. Leverone, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nicholas A. Saccomano, Ph.D.
Dr. Nicholas A. Saccomano, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Samuel Agresta, M.D.
Dr. Samuel Agresta, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrew Philips, Ph.D.
Dr. Andrew Philips, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Dylan Hartley, Ph.D.
Dr. Dylan Hartley, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ed T. Mathers ,
Ed T. Mathers ,
Independent Director
Independent Director
--
--
Ms. Valerie M. Jansen, M.D., Ph.D.
Ms. Valerie M. Jansen, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. R. Michael Carruthers
Mr. R. Michael Carruthers
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Isaac Manke, Ph.D.
Dr. Isaac Manke, Ph.D.
Independent Director
Independent Director
9.78K
+181.93%
Mr. Michael (Mike) Grey
Mr. Michael (Mike) Grey
Executive Director
Executive Director
--
--
Mr. Jason A. Leverone, CPA
Mr. Jason A. Leverone, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nicholas A. Saccomano, Ph.D.
Dr. Nicholas A. Saccomano, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Samuel Agresta, M.D.
Dr. Samuel Agresta, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrew Philips, Ph.D.
Dr. Andrew Philips, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
Acorn Capital Advisors, LLC
22.11%
Citadel Advisors LLC
8.48%
Shay Capital LLC
6.09%
The Vanguard Group, Inc.
5.50%
Cantor Fitzgerald, L.P
5.21%
其他
52.60%
持股股东
持股股东
占比
Acorn Capital Advisors, LLC
22.11%
Citadel Advisors LLC
8.48%
Shay Capital LLC
6.09%
The Vanguard Group, Inc.
5.50%
Cantor Fitzgerald, L.P
5.21%
其他
52.60%
股东类型
持股股东
占比
Investment Advisor
34.25%
Hedge Fund
24.32%
Investment Advisor/Hedge Fund
15.43%
Venture Capital
9.02%
Private Equity
3.83%
Individual Investor
1.66%
Research Firm
0.32%
其他
11.18%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
186
12.83M
100.04%
-1.08M
2025Q1
187
12.71M
99.28%
-1.05M
2024Q4
190
12.64M
105.50%
+4.22M
2024Q3
172
2.79M
546.32%
-1.40M
2024Q2
171
3.11M
93.03%
-1.12M
2024Q1
161
3.05M
91.28%
-864.58K
2023Q4
152
2.81M
85.98%
-309.72K
2023Q3
128
3.01M
91.00%
-83.83K
2023Q2
119
2.90M
88.58%
+621.98K
2023Q1
109
1.98M
78.98%
-170.10K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Acorn Capital Advisors, LLC
2.84M
22.14%
+1.40M
+97.24%
May 15, 2025
Citadel Advisors LLC
1.07M
8.33%
-6.21K
-0.58%
Mar 31, 2025
Shay Capital LLC
810.21K
6.32%
+659.18K
+436.43%
May 15, 2025
The Vanguard Group, Inc.
706.73K
5.51%
--
--
Mar 31, 2025
Cantor Fitzgerald, L.P
130.70K
1.02%
+95.00K
+266.11%
Mar 31, 2025
Highbridge Capital Management, LLC
438.80K
3.42%
+39.05K
+9.77%
Mar 31, 2025
Vestal Point Capital, LP
635.00K
4.95%
--
--
Mar 31, 2025
StepStone Group LP
491.94K
3.84%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
478.55K
3.73%
--
--
Mar 31, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
公告日期
类型
比率
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
